ARS Pharmaceuticals (SPRY) Expected to Announce Earnings on Monday

ARS Pharmaceuticals (NASDAQ:SPRY) is expected to announce its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect the company to announce earnings of ($0.42) per share and revenue of $25.5840 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Monday, March 9, 2026 at 8:30 AM ET.

ARS Pharmaceuticals Trading Down 0.7%

Shares of SPRY opened at $9.06 on Friday. The company has a current ratio of 6.66, a quick ratio of 6.51 and a debt-to-equity ratio of 1.14. The stock has a market cap of $895.58 million, a PE ratio of -11.19 and a beta of 0.78. ARS Pharmaceuticals has a 1 year low of $6.66 and a 1 year high of $18.90. The stock has a 50 day simple moving average of $10.20 and a 200-day simple moving average of $10.16.

Analysts Set New Price Targets

A number of brokerages have weighed in on SPRY. Zacks Research upgraded ARS Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of ARS Pharmaceuticals in a research note on Wednesday, January 21st. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, ARS Pharmaceuticals presently has an average rating of “Hold” and an average price target of $31.00.

Institutional Trading of ARS Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Creek Drive Management Group LLC bought a new position in ARS Pharmaceuticals in the fourth quarter valued at $3,447,000. FAS Wealth Partners Inc. lifted its position in ARS Pharmaceuticals by 0.9% during the 4th quarter. FAS Wealth Partners Inc. now owns 202,407 shares of the company’s stock worth $2,358,000 after buying an additional 1,787 shares in the last quarter. VARCOV Co. acquired a new position in shares of ARS Pharmaceuticals during the 4th quarter worth about $260,000. Osterweis Capital Management Inc. acquired a new position in shares of ARS Pharmaceuticals during the 4th quarter worth about $65,000. Finally, Millennium Management LLC bought a new position in shares of ARS Pharmaceuticals in the 4th quarter valued at about $36,912,000. 68.16% of the stock is currently owned by institutional investors and hedge funds.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.